Overview

A Study to Evaluate Efficacy and Safety of Zanubrutinib in Combination With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients

Status:
Not yet recruiting

Trial end date:
2026-01-01

Target enrollment:

Participant gender:

Summary

Zanubrutinib is a highly specific, potent new BTK inhibitor, with minimal off-target inhibition of other kinases. This is a single-arm, open-label Phase II study to evaluate the efficacy and safety of zanubrutinib in combination with R-CHOP in newly diagnosed non-GCB DLBCL patients with co-expression of BCL2 and MYC.

Phase:

Phase 2

Details

Lead Sponsor:

Fudan University

Treatments:

Zanubrutinib